Cargando…

Using a Pharmacy-Based Surveillance System to Improve Standards for TB Care in Kerala, India

INTRODUCTION: Eleven anti-TB drugs were included in the Government of India's Schedule H1 drug regulations in 2014. The National Strategic Plan for TB Elimination in India 2017–2025 recognized the opportunity to strengthen the TB surveillance system and improve the quality of TB care by impleme...

Descripción completa

Detalles Bibliográficos
Autores principales: PS, Rakesh, Balakrishnan, Shibu, Ramachandran, Rakesh, Nandhan, Smitha, Samuel, Nidhish Issac, PP, Pramodkumar, Aloysius, Suja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Global Health: Science and Practice 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8691886/
https://www.ncbi.nlm.nih.gov/pubmed/34933980
http://dx.doi.org/10.9745/GHSP-D-21-00346
_version_ 1784618841207209984
author PS, Rakesh
Balakrishnan, Shibu
Ramachandran, Rakesh
Nandhan, Smitha
Samuel, Nidhish Issac
PP, Pramodkumar
Aloysius, Suja
author_facet PS, Rakesh
Balakrishnan, Shibu
Ramachandran, Rakesh
Nandhan, Smitha
Samuel, Nidhish Issac
PP, Pramodkumar
Aloysius, Suja
author_sort PS, Rakesh
collection PubMed
description INTRODUCTION: Eleven anti-TB drugs were included in the Government of India's Schedule H1 drug regulations in 2014. The National Strategic Plan for TB Elimination in India 2017–2025 recognized the opportunity to strengthen the TB surveillance system and improve the quality of TB care by implementing the Schedule H1 regulation. However, there were no documented systematic large-scale efforts to use Schedule H1 regulation to support TB surveillance or improve the quality of care. We aimed to document the process of implementation of the Schedule H1 regulation to enhance the quality of TB care and strengthen the TB surveillance system in Kerala, India. METHODS: We conducted 33 in-depth interviews of the drugs control department enforcement officers, chemist shop owners, private-sector doctors, leaders of professional medical associations, and program managers and key staff of the TB Elimination Program in Kerala. Major themes identified were the process of implementation of Schedule H1 and how the National TB Elimination Program used the information. Findings from the qualitative interviews were corroborated with the quantitative information from the annual program performance reports and anti-TB drug sales data. RESULTS: The TB Elimination Program of Kerala used the information from the Schedule H1 drug register to identify the missing TB cases and strengthen TB notification, identify providers for engagement and extend support to them for ensuring standards of TB care, and provide feedback to providers regarding prescription practices. Stakeholders felt that implementation of Schedule H1 surveillance has helped to improve TB patient notifications from the private sector, build better public-private partnerships, and improve the quality of TB diagnosis and treatment in Kerala. CONCLUSION: Pharmacy-based drug sales data collected either through regulatory or non-regulatory methods have immense potential to support TB elimination programs.
format Online
Article
Text
id pubmed-8691886
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Global Health: Science and Practice
record_format MEDLINE/PubMed
spelling pubmed-86918862021-12-31 Using a Pharmacy-Based Surveillance System to Improve Standards for TB Care in Kerala, India PS, Rakesh Balakrishnan, Shibu Ramachandran, Rakesh Nandhan, Smitha Samuel, Nidhish Issac PP, Pramodkumar Aloysius, Suja Glob Health Sci Pract Original Article INTRODUCTION: Eleven anti-TB drugs were included in the Government of India's Schedule H1 drug regulations in 2014. The National Strategic Plan for TB Elimination in India 2017–2025 recognized the opportunity to strengthen the TB surveillance system and improve the quality of TB care by implementing the Schedule H1 regulation. However, there were no documented systematic large-scale efforts to use Schedule H1 regulation to support TB surveillance or improve the quality of care. We aimed to document the process of implementation of the Schedule H1 regulation to enhance the quality of TB care and strengthen the TB surveillance system in Kerala, India. METHODS: We conducted 33 in-depth interviews of the drugs control department enforcement officers, chemist shop owners, private-sector doctors, leaders of professional medical associations, and program managers and key staff of the TB Elimination Program in Kerala. Major themes identified were the process of implementation of Schedule H1 and how the National TB Elimination Program used the information. Findings from the qualitative interviews were corroborated with the quantitative information from the annual program performance reports and anti-TB drug sales data. RESULTS: The TB Elimination Program of Kerala used the information from the Schedule H1 drug register to identify the missing TB cases and strengthen TB notification, identify providers for engagement and extend support to them for ensuring standards of TB care, and provide feedback to providers regarding prescription practices. Stakeholders felt that implementation of Schedule H1 surveillance has helped to improve TB patient notifications from the private sector, build better public-private partnerships, and improve the quality of TB diagnosis and treatment in Kerala. CONCLUSION: Pharmacy-based drug sales data collected either through regulatory or non-regulatory methods have immense potential to support TB elimination programs. Global Health: Science and Practice 2021-12-31 /pmc/articles/PMC8691886/ /pubmed/34933980 http://dx.doi.org/10.9745/GHSP-D-21-00346 Text en © Rakesh PS et al. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly cited. To view a copy of the license, visit https://creativecommons.org/licenses/by/4.0/. When linking to this article, please use the following permanent link: https://doi.org/10.9745/GHSP-D-21-00346
spellingShingle Original Article
PS, Rakesh
Balakrishnan, Shibu
Ramachandran, Rakesh
Nandhan, Smitha
Samuel, Nidhish Issac
PP, Pramodkumar
Aloysius, Suja
Using a Pharmacy-Based Surveillance System to Improve Standards for TB Care in Kerala, India
title Using a Pharmacy-Based Surveillance System to Improve Standards for TB Care in Kerala, India
title_full Using a Pharmacy-Based Surveillance System to Improve Standards for TB Care in Kerala, India
title_fullStr Using a Pharmacy-Based Surveillance System to Improve Standards for TB Care in Kerala, India
title_full_unstemmed Using a Pharmacy-Based Surveillance System to Improve Standards for TB Care in Kerala, India
title_short Using a Pharmacy-Based Surveillance System to Improve Standards for TB Care in Kerala, India
title_sort using a pharmacy-based surveillance system to improve standards for tb care in kerala, india
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8691886/
https://www.ncbi.nlm.nih.gov/pubmed/34933980
http://dx.doi.org/10.9745/GHSP-D-21-00346
work_keys_str_mv AT psrakesh usingapharmacybasedsurveillancesystemtoimprovestandardsfortbcareinkeralaindia
AT balakrishnanshibu usingapharmacybasedsurveillancesystemtoimprovestandardsfortbcareinkeralaindia
AT ramachandranrakesh usingapharmacybasedsurveillancesystemtoimprovestandardsfortbcareinkeralaindia
AT nandhansmitha usingapharmacybasedsurveillancesystemtoimprovestandardsfortbcareinkeralaindia
AT samuelnidhishissac usingapharmacybasedsurveillancesystemtoimprovestandardsfortbcareinkeralaindia
AT pppramodkumar usingapharmacybasedsurveillancesystemtoimprovestandardsfortbcareinkeralaindia
AT aloysiussuja usingapharmacybasedsurveillancesystemtoimprovestandardsfortbcareinkeralaindia